Financial reports
ARS
2023 FY
Annual report to shareholders
13 Mar 24
10-K
2023 FY
Annual report
16 Feb 24
10-Q
2023 Q3
Quarterly report
27 Oct 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
10-Q
2023 Q1
Quarterly report
28 Apr 23
ARS
2023 FY
Annual report to shareholders
16 Mar 23
10-K
2022 FY
Annual report
16 Feb 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
10-Q
2022 Q2
Quarterly report
29 Jul 22
10-Q
2022 Q1
Quarterly report
29 Apr 22
Current reports
8-K/A
Johnson & Johnson Reports Q1 2024 Results
16 Apr 24
8-K
Johnson & Johnson Reports Q1 2024 Results
16 Apr 24
8-K
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
23 Jan 24
8-K
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
5 Dec 23
8-K
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review
5 Dec 23
8-K
Strengthens position in high-growth MedTech segments
30 Nov 23
8-K
Departure of Directors or Certain Officers
27 Nov 23
8-K
Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech
23 Oct 23
8-K
Results of Operations and Financial Condition
17 Oct 23
8-K
Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation
30 Aug 23
Registration and prospectus
SC TO-I/A
Issuer tender offer statement (amended)
23 Aug 23
425
Business combination disclosure
23 Aug 23
SC TO-I/A
Issuer tender offer statement (amended)
21 Aug 23
425
Business combination disclosure
21 Aug 23
425
Business combination disclosure
18 Aug 23
425
Business combination disclosure
17 Aug 23
SC TO-I/A
Issuer tender offer statement (amended)
17 Aug 23
425
Business combination disclosure
16 Aug 23
425
Business combination disclosure
16 Aug 23
425
Business combination disclosure
16 Aug 23
Proxies
DFAN14A
Additional proxy materials by non-management
5 Apr 24
PX14A6G
Letter to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEF 14A
Definitive proxy
13 Mar 24
DFAN14A
Additional proxy materials by non-management
15 Feb 24
DFAN14A
Additional proxy materials by non-management
29 Jan 24
DFAN14A
Additional proxy materials by non-management
9 Jan 24
DFAN14A
Additional proxy materials by non-management
8 Jan 24
DEFA14A
Additional proxy soliciting materials
8 Jan 24
Other
SD
Conflict minerals disclosure
24 May 23
SD
Conflict minerals disclosure
26 May 22
SD
Conflict minerals disclosure
27 May 21
UPLOAD
Letter from SEC
27 May 21
CORRESP
Correspondence with SEC
4 May 21
UPLOAD
Letter from SEC
27 Apr 21
SD
Conflict minerals disclosure
28 May 20
UPLOAD
Letter from SEC
20 Sep 19
CORRESP
Correspondence with SEC
22 Aug 19
CORRESP
Correspondence with SEC
24 Jul 19
Ownership
SC 13G
Contineum Therapeutics, Inc.
10 Apr 24
3
Contineum Therapeutics, Inc.
10 Apr 24
4
Vanessa Broadhurst
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
Eugene A. Woods
7 Mar 24
4
MARILLYN A HEWSON
7 Mar 24
4
CVRx, Inc.
6 Mar 24
4
Jennifer L Taubert
20 Feb 24
4
Kathryn E Wengel
20 Feb 24
4
Timothy Schmid
20 Feb 24